Patents Issued in January 25, 2018
  • Publication number: 20180021255
    Abstract: A chewable pharmaceutical product comprises a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally a flavoring, wherein the binder comprises one or more maltitol syrups, which are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and colesevelam hydrochloride.
    Type: Application
    Filed: July 21, 2016
    Publication date: January 25, 2018
    Inventor: Tommy L. Chau
  • Publication number: 20180021256
    Abstract: The present invention relates to a novel process used for the preparation of dry powder formulations for inhalation.
    Type: Application
    Filed: July 8, 2015
    Publication date: January 25, 2018
    Inventors: ALI TÜRKYILMAZ, DEVRIM CELIK, ÖZLEM AKDAS
  • Publication number: 20180021257
    Abstract: A water-soluble pharmaceutical composition comprises at least one therapeutically active substance and at least one substance capable of forming micelles, wherein the therapeutically active substance is selected from drugs having hydrophobic properties for treating cancer patients, and the at least one substance capable of forming micelles is selected from antibiotics of the lipoglycopeptide type, such as teicoplanin, dalbavancin and oritavancin.
    Type: Application
    Filed: January 28, 2016
    Publication date: January 25, 2018
    Inventors: Dante Miguel BELTRAMO, Roxana Valeria ALASINO, Nestor GARCIA
  • Publication number: 20180021258
    Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents.
    Type: Application
    Filed: December 31, 2015
    Publication date: January 25, 2018
    Inventors: Barney S. GRAHAM, Masaru KANEKIYO, Hadi M. YASSINE
  • Publication number: 20180021259
    Abstract: Described herein are nanoparticles which are largely made of (e.g., 90 wt. %) hydrophobic drugs and are stabilized by water soluble dyes. The nanoparticles can range in size from 30 nm to 150 nm and have highly negative surface charge (e.g., ?55 mV). These nanoparticles are highly soluble in water, stable for days in PBS buffer and can be easily lyophilzed and reconstituted in water. Using quantitative self-assembly prediction calculations, topochemical molecular descriptors were identified and validated as highly predictive indicators of nano-assembly, nanoparticle size, and drug loading. The resulting nanoparticles selectively targeted kinase inhibitors to caveolin-1-expressing human colon cancer and autochthonous liver cancer models to yield striking therapeutic effects while avoiding pERK inhibition in healthy skin. The nanoparticles exhibited remarkable anti-tumor efficacy in vitro and in vivo in models of hepatocellular carcinoma.
    Type: Application
    Filed: February 9, 2016
    Publication date: January 25, 2018
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Daniel A. HELLER, Yosef SHAMAY
  • Publication number: 20180021260
    Abstract: The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.
    Type: Application
    Filed: August 10, 2017
    Publication date: January 25, 2018
    Inventor: Steven R. Little
  • Publication number: 20180021261
    Abstract: An oil-in-water emulsion comprises an emulsifier which is a non-gelled branched polymer (e.g. a branched vinyl polymer), wherein the ends of at least some of the chains of said polymer terminate in an alkyl chain of 5 carbon atoms or more, and wherein the oil-in-water emulsion takes the form of particles having a z-average diameter of no greater than about 1000 nm. This is useful in, for example, facilitating the carrying of hydrophobic materials within aqueous systems, to enhance oral drug delivery. The oil-in-water emulsion may be prepared by mixing an oil phase with an aqueous phase in the presence of an emulsifier, wherein said emulsifier is a non-gelled branched polymer, wherein the ends of at least some of the chains of said polymer terminate in an alkyl chain of 5 carbon atoms or more, and wherein the oil-in-water emulsion takes the form of particles having a z-average diameter of no greater than about 1000 nm.
    Type: Application
    Filed: February 3, 2016
    Publication date: January 25, 2018
    Applicant: The University of Liverpool
    Inventors: Steve Rannard, Andrew Owen, James Hobson, Neill Liptrott, Pierre Chambon
  • Publication number: 20180021262
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 25, 2018
    Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20180021263
    Abstract: The present invention relates to a method of producing a direct compression tablet composition comprising the step of processing ibuprofen, a hydrophilic polymer, and an inorganic excipient by an extrusion process to produce an extruded composition in which the ibuprofen forms a solid dispersion/solution within the hydrophilic polymer. The invention is particularly useful in preparing oral dissolvable tablets. Also provided are composition comprising an inorganic excipient and ibuprofen within a hydrophilic polymer.
    Type: Application
    Filed: February 9, 2016
    Publication date: January 25, 2018
    Inventors: Dennis Douroumis, Mohammed Maniruzzaman, Saumil Kiritkumar Bhatt, Anwar Ali, Arun Jangra
  • Publication number: 20180021264
    Abstract: The present invention relates to a product, method of making and method of using an albumin sphere suspension for controlling bleeding of a non-thrombocytopenic patient before, during and after surgery. An albumin sphere suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of controlling bleeding in vivo. The suspension is prepared by mixing at near freezing temperatures an albumin solution, a sub-stabilizing concentration of glutaraldehyde solution and an alcohol solution containing a stabilizing concentration of glutaraldehyde. The mixed suspension is warmed, and glycine and sorbitol being added. Lyophilization of the suspension can be performed for stabilization of the suspension.
    Type: Application
    Filed: June 9, 2017
    Publication date: January 25, 2018
    Inventor: Richard C. K. Yen
  • Publication number: 20180021265
    Abstract: Methods and compositions described herein use polysaccharide nanoparticles (or polysaccharide-coated nanoparticles) to retain and deliver unaltered therapeutic agents to sites of disease. The polysaccharide nanoparticles are non-covalently associated with the unaltered therapeutic agent. The polysaccharide is able to retain cargo (drugs, diagnostics, etc.) without chemical modification of the agent. The nanoparticle maintains its association with the agent through non-covalent interactions but releases its agent in response to changes in the microenvironment, e.g., at the site of cancer cells or cancer tissue.
    Type: Application
    Filed: February 17, 2016
    Publication date: January 25, 2018
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Jan GRIMM, Charalambos KAITTANIS, Travis M. SHAFFER
  • Publication number: 20180021266
    Abstract: An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer.
    Type: Application
    Filed: June 8, 2017
    Publication date: January 25, 2018
    Inventors: Evan C. Unger, Edmund R. Marinelli
  • Publication number: 20180021267
    Abstract: The present invention relates to compositions and methods comprising resveratrol and uses thereof. Some embodiments include compositions and methods with increased bioavailability of resveratrol. Certain embodiments include compositions comprising resveratrol and a solubilizer. Particular embodiments include transmucosal delivery of resveratrol from the composition.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 25, 2018
    Inventor: Otis L. Blanchard
  • Publication number: 20180021268
    Abstract: A composition for weight loss comprising at least 8% total chalcones comprising 4-hydroxyderricin and xanthoangelol and coumarins. A composition for reduction of visceral fat comprising at least 8% total chalcones comprising 4-hydroxyderricin and xanthoangelol and coumarins. A method to isolate and purify chalcones.
    Type: Application
    Filed: July 14, 2017
    Publication date: January 25, 2018
    Applicant: JBSL-USA, INCORPORATED
    Inventor: Vincent Hackel
  • Publication number: 20180021269
    Abstract: The present invention relates to uses of a benzophenone compound and analogues thereof having a symmetrical core structure and having same or different number of hydroxyl substitutions in benzene rings in the preparation of drugs for preventing and treating viral infections and anti-tumor drugs, in particular the use in the preparation of drugs for preventing and treating HIV, herpes virus and papillomavirus infection and the diseases induced thereby, wherein such viral infections include AIDS, genital warts, flat warts, common warts, herpes simplex, herpes zoster, vaginitis, cervicitis, cervical erosion and senile dementia, as well as cervical cancer, lung cancer, gastric cancer and colon cancer induced thereby, by means of preparing the hydroxy-substituted benzophenones and analogues thereof together with various compatible excipients into different medicaments or personal disinfected sanitary articles.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 25, 2018
    Inventors: Weihua QIN, Guangyu JIANG
  • Publication number: 20180021270
    Abstract: Presented herein are methods for the treatment of oncological disorders by the co-administration of Coenzyme Q10 and immune checkpoint modulators. The Coenzyme Q10 formulations may be at least one of intravenous, topical, or by inhalation. Co-administration of the Coenzyme Q10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.
    Type: Application
    Filed: July 21, 2017
    Publication date: January 25, 2018
    Inventors: Maria Dorothea Nastke, Shiva Kazerounian, Anne R. Diers, Vivek K. Vishnudas, Stephane Gesta, Rangaprasad Sarangarajan, Niven Rajin Narain
  • Publication number: 20180021271
    Abstract: The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula I wherein R1-R9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases.
    Type: Application
    Filed: September 26, 2017
    Publication date: January 25, 2018
    Inventors: Gary Paul COOK, Garry Thomas GWOZDZ, Theodore Patrick LASLO
  • Publication number: 20180021272
    Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.
    Type: Application
    Filed: February 9, 2016
    Publication date: January 25, 2018
    Applicant: Entera Bio Ltd.
    Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Philip M. SCHWARTZ, Hillel GALITZER
  • Publication number: 20180021273
    Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.
    Type: Application
    Filed: July 20, 2017
    Publication date: January 25, 2018
    Inventors: Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL, Donald W. LANDRY, Ottavio ARANCIO, Luigi SCOTTO, Shi Xian DENG, Rosa PURGATORIO, Jole FIORITO
  • Publication number: 20180021274
    Abstract: ?-hydroxybutyric acid in combination with ?-hydroxybutyrate salts are useful to induce ketosis, achieving blood ketone levels of (0.5-6.0 mmol/L), with or without dietary restriction, and without inducing harmfully high mineral loads in the blood. The combination of ?-hydroxybutyric acid and salt results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance & endurance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. These acid/salt mixtures are also useful for suppressing appetite, preventing epileptic seizures, and treating cancer.
    Type: Application
    Filed: March 27, 2017
    Publication date: January 25, 2018
    Inventor: Patrick Arnold
  • Publication number: 20180021275
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for inhibiting or treating idiopathic pulmonary fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.
    Type: Application
    Filed: July 5, 2017
    Publication date: January 25, 2018
    Applicant: MediciNova, Inc.
    Inventors: Kazuko MATSUDA, Yuichi IWAKI
  • Publication number: 20180021276
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Application
    Filed: July 19, 2017
    Publication date: January 25, 2018
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Publication number: 20180021277
    Abstract: A method of treating a bacterial infection in a subject in need thereof includes administering to the subject an AgrA antagonist.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 25, 2018
    Inventors: Menachem Shoham, Rajesh Viswanathan, Guanping Yu
  • Publication number: 20180021278
    Abstract: Methods and compositions are provided that treat or prevent inflammation using serine. A therapeutically effective amount of serine is administered to an individual, for example a human or other mammal, that has inflammation or is at risk of inflammation. The methods and compositions can control and/or alleviate an inflammatory reaction of the body, such as colitis.
    Type: Application
    Filed: January 22, 2016
    Publication date: January 25, 2018
    Inventors: Magali Faure, Stephanie Blum-Sperisen, Mohamed Nabil Bosco, Viral Brahmbhatt, Denis Breuille
  • Publication number: 20180021279
    Abstract: A specialized immunonutrition supplement can be administered to a surgical patient to reduce post-operative complications by restraining the expansion of myeloid-derived suppressor cells. The supplement includes one or more of L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides, preferably all four of these compounds. The supplement is administered to the patient at least once per day for a time period extending from a pre-operative day that is three to seven days prior to a bladder surgery of the patient to a post-operative day that is three to seven days after the bladder surgery. The supplement can be administered to treat or prevent post-operative paralytic ileus in a bladder cancer patient; treat or prevent surgery-induced, inflammation-induced or cancer-induced cachexia; reduce the incidence of chronic infections resulting from expansion of myeloid-derived suppressor cells in a patient; and/or reduce mRNA expression of pro-inflammatory cytokines in a patient.
    Type: Application
    Filed: February 15, 2016
    Publication date: January 25, 2018
    Inventors: Jill Hamilton-Reeves, Jeffrey M. Holzbeierlein, Thomas Yankee
  • Publication number: 20180021280
    Abstract: The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.
    Type: Application
    Filed: July 20, 2017
    Publication date: January 25, 2018
    Applicant: AbbVie Inc.
    Inventors: Alexandru DEAC, Ye HUANG, John M. LIPARI, Alexander RUGGLES, Thin Yu TUN
  • Publication number: 20180021281
    Abstract: Provided herein is technology relating to compositions containing bioactive non-methylene interrupted fatty acids (NMIFAs) in combination with short chain fatty acids, medium chain fatty acids, ketone bodies and/or endocannabinoids and endocannabinoid-related mediators, and particularly, but not exclusively, to compositions and methods related to the production and use of non-methylene interrupted fatty acids such as sciadonic acids, juniperonic acid, pinoleic acid and dihomopinoleic acid in combination with short chain fatty acids, medium chain fatty acids and/or endocannabinoids and endocannabinoid-related mediators.
    Type: Application
    Filed: July 19, 2017
    Publication date: January 25, 2018
    Inventor: Alvin Berger
  • Publication number: 20180021282
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: May 3, 2017
    Publication date: January 25, 2018
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Publication number: 20180021283
    Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating lupus erythematosus. The chlorogenic acid can improve an immunity function. The present invention provides a preparation for treating lupus erythematosus, comprising chlorogenic acid and pharmaceutically acceptable auxiliary materials. The present invention further provides a combined medicine comprising chlorogenic acid and medicines for treating lupus erythematosus.
    Type: Application
    Filed: January 26, 2016
    Publication date: January 25, 2018
    Inventors: Jie ZHANG, Wang HUANG, Xiaoguang CHEN
  • Publication number: 20180021284
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Application
    Filed: July 21, 2017
    Publication date: January 25, 2018
    Inventors: Claire Mégret, Hervé Guillard, Jean-François DUBUISSON
  • Publication number: 20180021285
    Abstract: Provided are compositions and methods for visualizing the skeletal tissues of a biological specimen, comprising treating the specimen with a calcium chelating agent, a staining solution, and a clearing solution.
    Type: Application
    Filed: July 25, 2017
    Publication date: January 25, 2018
    Inventors: Nicholas Ingram Crider, Thomas Steven Villani, JR., Michael Thomas Johnson
  • Publication number: 20180021286
    Abstract: Stabilized liquid, suspension or gel compositions containing a dialkyl fumarate and comprising a vehicle which serves as a protective base, a pharmaceutically acceptable surfactant, and a pharmaceutically acceptable acidulant, and methods of preparing such compositions are disclosed. Capsules and other dosage forms containing the stabilized liquid, suspension or gel compositions are also disclosed.
    Type: Application
    Filed: January 29, 2016
    Publication date: January 25, 2018
    Applicant: Enspire Group LLC
    Inventors: Abdul Rashid, Zhang Julia Zhang, Minh Tran, Dahai Guo, Yi Zeng, Charchil Vejani, Hengsheng Adam Feng
  • Publication number: 20180021287
    Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine disease, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.
    Type: Application
    Filed: June 30, 2017
    Publication date: January 25, 2018
    Inventors: Alexandra DURR, Fanny MOCHEL
  • Publication number: 20180021288
    Abstract: Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: wherein R1 and R2 are independently selected from OH, O?, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.
    Type: Application
    Filed: July 7, 2017
    Publication date: January 25, 2018
    Applicant: Biogen MA Inc.
    Inventors: Susan Goelz, Katherine Dawson, Ralf Linker, Ralf Gold
  • Publication number: 20180021289
    Abstract: The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF). More specifically, the present invention relates to a pharmaceutical composition for oral use in treating psoriasis by administering a low daily dosage in the range of 375 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.
    Type: Application
    Filed: October 3, 2017
    Publication date: January 25, 2018
    Inventors: Christin GALETZKA, Chris RUNDFELDT, Roland RUPP, Peder M. ANDERSEN
  • Publication number: 20180021290
    Abstract: A topical pharmaceutical composition containing diacerein and/or its analogs is provided. Also provided is a method for treating various diseases using this topical pharmaceutical composition.
    Type: Application
    Filed: July 25, 2017
    Publication date: January 25, 2018
    Inventors: Chih-Kuang Chen, Jing-Yi Lee, Wei-Shu Lu, Carl Oscar Brown, III
  • Publication number: 20180021291
    Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
    Type: Application
    Filed: August 25, 2017
    Publication date: January 25, 2018
    Inventors: Bruce SCHARSCHMIDT, Masoud MOKHTARANI
  • Publication number: 20180021292
    Abstract: The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age.
    Type: Application
    Filed: September 8, 2017
    Publication date: January 25, 2018
    Inventors: Bruce SCHARSCHMIDT, Masoud MOKHTARANI
  • Publication number: 20180021293
    Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
    Type: Application
    Filed: September 8, 2017
    Publication date: January 25, 2018
    Inventors: Bruce SCHARSCHMIDT, Masoud MOKHTARANI
  • Publication number: 20180021294
    Abstract: EphA2-targeted immunoliposomes for delivering docetaxel are useful in the treatment of certain types of cancer. The immunoliposomes can include an EphA2 targeting moiety (e.g., a scFv) and encapsulate a docetaxel prodrug in a stable salt form within a liposome having an average size of about 100 nm. Novel docetaxel prodrugs suitable for loading into nanoliposomes (including immunoliposomes) are provided, along with novel and other useful EphA2 targeting moieties for preparation of EphA2-targeted doxorubicin-generating immunoliposome therapies. Pharmaceutical compositions can be prepared that include nanoliposomes encapsulating one or more docetaxel prodrugs, and/or immunoliposomes or nanoparticles comprising an EphA2 binding moiety and encapsulating one or more docetaxel prodrugs. The pharmaceutical compositions are useful for administration to a patient for the treatment of cancer.
    Type: Application
    Filed: March 16, 2017
    Publication date: January 25, 2018
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Zhaohua R. Huang, Suresh K. Tipparaju, Charles Noble
  • Publication number: 20180021295
    Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.
    Type: Application
    Filed: February 17, 2016
    Publication date: January 25, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
  • Publication number: 20180021296
    Abstract: The object of the invention is to provide a potentiated antimicrobial agent for use in treating a microbial infection, characterized in that the antimicrobial agent is used in combination with a compound of the following formula I: in a compound of formula (I): antimicrobial agent mass ratio, ranging from 8:1 to 1:10 and in that the microbial infection is induced in particular by a strain A pathogen and in that on this strain A, the concentration of compound (I) meets the following equation: [C]<[MIC]/x where [C] is the concentration according to the invention of compound (I) to be used on the strain A [MIC] is the MIC measured for the compound (I), alone, on this strain A x is higher than or equal to 100, advantageously to 1 000, more advantageously x is between 2 000 and 10 000, or even higher than 50 000.
    Type: Application
    Filed: September 15, 2015
    Publication date: January 25, 2018
    Applicant: SEPTEOS
    Inventor: Nicolas TESSE
  • Publication number: 20180021297
    Abstract: Provided are combination therapy methods and uses for treating diarrhea, particularly malabsorption diarrhea, in neonatal, young and adult non-human animals, particularly for treating diarrhea resulting from microbial infection of the animals, with a therapeutically effective amount of a proanthocyanidin polymer from Croton lechleri, in either enteric or non-enteric form, in combination with a therapeutically effective amount of the antimicrobial agent rifaximin.
    Type: Application
    Filed: February 24, 2016
    Publication date: January 25, 2018
    Inventor: Michael Hauser
  • Publication number: 20180021298
    Abstract: The invention provides a method for improving growth performance animals. In particularly, the inventors of the invention found that the addition of a proteolytic enzyme (protease) to regular animal diets results in a significant improvement of growth performance if the proteolytic enzyme is supplemented and combined with vitamin C.
    Type: Application
    Filed: February 10, 2016
    Publication date: January 25, 2018
    Inventors: Aaron COWIESON, Inge KNAP
  • Publication number: 20180021299
    Abstract: The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.
    Type: Application
    Filed: March 3, 2008
    Publication date: January 25, 2018
    Inventors: Thomas M. Hallam, Tim Tully, Rusiko Bourtchouladze
  • Publication number: 20180021300
    Abstract: Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.
    Type: Application
    Filed: July 21, 2017
    Publication date: January 25, 2018
    Inventors: Nicholas S. BODOR, John J. KOLENG, David ANGULO
  • Publication number: 20180021301
    Abstract: The stable aerosol solution formulations comprising glycopyrronium chloride are useful for administration to patients with COPD and other respiratory conditions.
    Type: Application
    Filed: September 7, 2017
    Publication date: January 25, 2018
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
  • Publication number: 20180021302
    Abstract: The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.
    Type: Application
    Filed: February 12, 2016
    Publication date: January 25, 2018
    Inventors: Nicolas CHARLES, Christophe PELLEFIGUES
  • Publication number: 20180021303
    Abstract: The present invention relates to BKCa activators for use in the treatment of a muscular disorder, or for controlling spasticity or tremors, for example, spasticity in MS.
    Type: Application
    Filed: February 12, 2016
    Publication date: January 25, 2018
    Inventors: David Selwood, David Baker
  • Publication number: 20180021304
    Abstract: The present invention relates to a composition comprising cebranopadol in dissolved form and oral dosage forms comprising said composition. The invention further relates to a process for producing the composition comprising cebranopadol in dissolved form and to the corresponding process of producing an oral dosageform containing the composition of the invention.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 25, 2018
    Inventors: Wolfgang ALBRECHT, Jens Geier, Frank LEHMANN